Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent adult Hodgkin lymphoma, stage III adult Hodgkin lymphoma, stage IV adult Hodgkin lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically* confirmed Hodgkin's lymphoma meeting ≥ 1 of the following criteria: Disease progression during initial first line chemotherapy Complete response lasting ≤ 90 days after induction Partial response lasting ≤ 90 days after induction First recurrence/progression with the duration of initial response ≤ 12 months after completion of chemotherapy NOTE: *There must be unequivocal radiological evidence of recurrent or progressive disease if biopsy was not obtained at time of disease recurrence/progression No clonal abnormalities in marrow collection Must have bilateral or unilateral bone marrow aspirates and biopsy within 42 days prior to stem cell collection Must have adequate sections of original diagnostic specimen available for review Needle aspirations or cytologies are not adequate No prior lymphoma, myelodysplastic syndromes, or leukemia (even if disease free ≥ 5 years) No CNS involvement PATIENT CHARACTERISTICS: Performance status Karnofsky 50-100% Life expectancy Not specified Hematopoietic Not specified Hepatic Bilirubin ≤ 1.5 times upper limit of normal* (ULN) NOTE: *Unless due to Hodgkin's lymphoma Renal Creatinine clearance ≥ 60 mL/min Creatinine ≤ 2.0 times ULN Cardiovascular Ejection fraction ≥ 45% by 2-D echocardiogram No significant active cardiac disease Pulmonary Adequate pulmonary function DLCO ≥ 45% Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer No known HIV or AIDS infection No active bacterial, fungal, or viral infection No medical condition that would preclude study treatment PRIOR CONCURRENT THERAPY: Chemotherapy See Disease Characteristics Surgery See Disease Characteristics
Sites / Locations
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Poor Risk
Good Risk
Primary progressive, recurrent, or resistant relapse patients
First recurrence patients